Arch Biopartners Inc.
ARCH.VTSXVHealthcare● Active
$0.48
$-0.02(-3.06%)
Market Cap$32268312
P/E Ratio—
52W High$1.95
52W Low$0.39
Arch Biopartners Inc. (ARCH.V) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ARCH.V · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | — | -78.05% | -6.50% | -52.14% | -3.86% |
| Operating Expenses | |||||
| R&D Expenses | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Operating Income | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | -186.00% | -169.10% | -143.99% | -29.97% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Margin %(computed) | — | -184.73% | -167.69% | -145.95% | -30.10% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.02 | $-0.06 | $-0.05 | $-0.02 | $-0.02 |
| Wtd Avg Shares | 0.07B | 0.06B | 0.06B | 0.06B | 0.06B |
| EBITDA | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| EBITDA Margin %(computed) | — | -166.39% | -16.94% | -10.47% | -1.98% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CAD · B
Explore more Arch Biopartners Inc. data
About Arch Biopartners Inc. (ARCH.V) Income Statement
Arch Biopartners Inc. (ARCH.V) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ARCH.V reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.00B) — a net profit margin of —.
Frequently asked questions
ARCH.V · 4 questionsArch Biopartners Inc. (ARCH.V) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
ARCH.V revenueARCH.V salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08